Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in Rapidly Progressive Interstitial Lung Disease
NCT07737249Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in interstitial lung disease (ILD), sponsored by Peking Union Medical College Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07737249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737249.